These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 21930666)

  • 1. Virologic suppression in nevirapine-exposed HIV-infected infants initiating antiretroviral therapy in rural Uganda.
    Kay J; Wanzira H; Sandison T; Kakuru A; Bigira V; Kamya M; Homsy J; Tappero JW; Havlir D; Dorsey G; Ruel T
    J Trop Pediatr; 2012 Jun; 58(3):194-9. PubMed ID: 21930666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nevirapine- Versus Lopinavir/Ritonavir-Based Antiretroviral Therapy in HIV-Infected Infants and Young Children: Long-term Follow-up of the IMPAACT P1060 Randomized Trial.
    Barlow-Mosha L; Angelidou K; Lindsey J; Archary M; Cotton M; Dittmer S; Fairlie L; Kabugho E; Kamthunzi P; Kinikar A; Mbengeranwa T; Msuya L; Sambo P; Patel K; Barr E; Jean-Phillipe P; Violari A; Mofenson L; Palumbo P; Chi BH
    Clin Infect Dis; 2016 Oct; 63(8):1113-1121. PubMed ID: 27439527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial.
    Lockman S; Hughes M; Sawe F; Zheng Y; McIntyre J; Chipato T; Asmelash A; Rassool M; Kimaiyo S; Shaffer D; Hosseinipour M; Mohapi L; Ssali F; Chibowa M; Amod F; Halvas E; Hogg E; Alston-Smith B; Smith L; Schooley R; Mellors J; Currier J;
    PLoS Med; 2012; 9(6):e1001236. PubMed ID: 22719231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
    Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
    Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to antiretroviral therapy in HIV-infected Ugandan children exposed and not exposed to single-dose nevirapine at birth.
    Musoke PM; Barlow-Mosha L; Bagenda D; Mudiope P; Mubiru M; Ajuna P; Tumwine JK; Fowler MG
    J Acquir Immune Defic Syndr; 2009 Dec; 52(5):560-8. PubMed ID: 19950430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minor resistant variants in nevirapine-exposed infants may predict virologic failure on nevirapine-containing ART.
    MacLeod IJ; Rowley CF; Thior I; Wester C; Makhema J; Essex M; Lockman S
    J Clin Virol; 2010 Jul; 48(3):162-7. PubMed ID: 20427228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment outcomes among HIV-1 and HIV-2 infected children initiating antiretroviral therapy in a concentrated low prevalence setting in West Africa.
    Okomo U; Togun T; Oko F; Peterson K; Townend J; Peterson I; Jaye A
    BMC Pediatr; 2012 Jul; 12():95. PubMed ID: 22770231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early virological suppression with three-class antiretroviral therapy in HIV-infected African infants.
    Prendergast A; Mphatswe W; Tudor-Williams G; Rakgotho M; Pillay V; Thobakgale C; McCarthy N; Morris L; Walker BD; Goulder P
    AIDS; 2008 Jul; 22(11):1333-43. PubMed ID: 18580613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission.
    Lindsey JC; Hughes MD; Violari A; Eshleman SH; Abrams EJ; Bwakura-Dangarembizi M; Barlow-Mosha L; Kamthunzi P; Sambo PM; Cotton MF; Moultrie H; Khadse S; Schimana W; Bobat R; Zimmer B; Petzold E; Mofenson LM; Jean-Philippe P; Palumbo P;
    Pediatr Infect Dis J; 2014 Aug; 33(8):846-54. PubMed ID: 25222305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The long-term effectiveness of generic adult fixed-dose combination antiretroviral therapy for HIV-infected Ugandan children.
    Barlow-Mosha LN; Bagenda DS; Mudiope PK; Mubiru MC; Butler LM; Fowler MG; Musoke PM
    Afr Health Sci; 2012 Sep; 12(3):249-58. PubMed ID: 23382737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Response to nonnucleoside reverse transcriptase inhibitor-based therapy in HIV-infected children with perinatal exposure to single-dose nevirapine.
    Musiime V; Ssali F; Kayiwa J; Namala W; Kizito H; Kityo C; Mugyenyi P
    AIDS Res Hum Retroviruses; 2009 Oct; 25(10):989-96. PubMed ID: 19778270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nevirapine Resistance in Previously Nevirapine-Unexposed HIV-1-Infected Kenyan Infants Initiating Early Antiretroviral Therapy.
    Chohan BH; Tapia K; Benki-Nugent S; Khasimwa B; Ngayo M; Maleche-Obimbo E; Wamalwa D; Overbaugh J; John-Stewart G
    AIDS Res Hum Retroviruses; 2015 Aug; 31(8):783-91. PubMed ID: 25819584
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risk of tuberculosis after antiretroviral treatment initiation: a comparison between efavirenz and nevirapine using inverse probability weighting.
    Hermans SM; Manabe YC; Kiragga AN; Hoepelman AI; Lange JM; van Leth F
    Antivir Ther; 2013; 18(4):615-22. PubMed ID: 23423604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of nevirapine- and efavirenz-containing antiretroviral regimens in antiretroviral-naïve patients: a cohort study.
    Keiser P; Nassar N; White C; Koen G; Moreno S
    HIV Clin Trials; 2002; 3(4):296-303. PubMed ID: 12187503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nevirapine/zidovudine/lamivudine has superior immunological and virological responses not reflected in clinical outcomes in a 48-week randomized comparison with abacavir/zidovudine/lamivudine in HIV-infected Ugandan adults with low CD4 cell counts.
    Munderi P; Walker AS; Kityo C; Babiker AG; Ssali F; Reid A; Darbyshire JH; Grosskurth H; Mugyenyi P; Gibb DM; Gilks CF;
    HIV Med; 2010 May; 11(5):334-44. PubMed ID: 20136661
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching children previously exposed to nevirapine to nevirapine-based treatment after initial suppression with a protease-inhibitor-based regimen: long-term follow-up of a randomised, open-label trial.
    Kuhn L; Coovadia A; Strehlau R; Martens L; Hu CC; Meyers T; Sherman G; Hunt G; Persaud D; Morris L; Tsai WY; Abrams EJ
    Lancet Infect Dis; 2012 Jul; 12(7):521-30. PubMed ID: 22424722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Community Based Antiretroviral Treatment in Rural Zimbabwe.
    Chimukangara B; Manasa J; Mitchell R; Nyabadza G; Katzenstein D; Masimirembwa C
    AIDS Res Hum Retroviruses; 2017 Dec; 33(12):1185-1191. PubMed ID: 28899102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Younger Age Predicts Failure to Achieve Viral Suppression and Virologic Rebound Among HIV-1-Infected Persons in Serodiscordant Partnerships.
    Mujugira A; Celum C; Tappero JW; Ronald A; Mugo N; Baeten JM
    AIDS Res Hum Retroviruses; 2016 Feb; 32(2):148-54. PubMed ID: 26670218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of peer support on virologic failure in HIV-infected patients on antiretroviral therapy - a cluster randomized controlled trial in Vietnam.
    Cuong DD; Sönnerborg A; Van Tam V; El-Khatib Z; Santacatterina M; Marrone G; Chuc NT; Diwan V; Thorson A; Le NK; An PN; Larsson M
    BMC Infect Dis; 2016 Dec; 16(1):759. PubMed ID: 27986077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Virologic Response to First-line Efavirenz- or Nevirapine-based Antiretroviral Therapy in HIV-infected African Children.
    Kekitiinwa A; Szubert AJ; Spyer M; Katuramu R; Musiime V; Mhute T; Bakeera-Kitaka S; Senfuma O; Walker AS; Gibb DM;
    Pediatr Infect Dis J; 2017 Jun; 36(6):588-594. PubMed ID: 28505015
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.